IRIS Archives

Information and Referral and Internet Sightings

IRIS@LISTSERV.ICORS.ORG

Options: Use Forum View

Use Monospaced Font
Show Text Part by Default
Show All Mail Headers

Message: [<< First] [< Prev] [Next >] [Last >>]
Topic: [<< First] [< Prev] [Next >] [Last >>]
Author: [<< First] [< Prev] [Next >] [Last >>]

Print Reply
Subject:
From:
Sylvia Caras <[log in to unmask]>
Reply To:
Date:
Mon, 12 Aug 2013 17:49:56 -0700
Content-Type:
text/plain
Parts/Attachments:
text/plain (19 lines)
Medicaid spends more on antipsychotics – 
including Eli Lilly’s (LLY) Zyprexa, 
Bristol-Myers Squibb's (BMY) Abilify, 
AstraZeneca’s (AZN) Seroquel and Johnson & 
Johnson’s (JNJ) Risperdal - than any other class of medicine.

In 2008, the most recent year for which data was 
available, spending was $3.6 billion, up from 
$1.6 billion in 1999, according to Mathematica 
Policy Research data cited by the paper. And the 
number of people younger than 20 years old who 
receive prescriptions for antipsychotics that are 
paid for by Medicaid tripled during that period.

http://www.pharmalive.com/feds-probe-antipsychotic-prescriptions-for-children-in-medicaid?cid=nl.phrm01


"People Who experience mood swings, fear, voices and visions"

ATOM RSS1 RSS2